Certara’s Senior Vice President, Chris Bouton, Head of Artificial Intelligence recognized for his technical innovation, entrepreneurship, and leadership.
RADNOR, Pa. — 10월 10, 2024 – Certara, Inc. 글로벌 바이오시뮬레이션 선두기업(Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced that Chris Bouton, Ph.D., Senior Vice President, Head of Artificial Intelligence (AI), has been recognized as an industry leader by the 2024 PharmaVoice 100.
Dr. Bouton has dedicated his career to using AI to help increase the efficiency of the drug discovery and development process. A serial entrepreneur in the life sciences industry, Dr. Bouton came to Certara in 2022 as the Founder and CEO of acquired Vyasa Analytics. He is the driving force behind the Certara.AI platform. This software uses secure, flexible, life science-specific generative pre-trained transformers (GPTs) to accelerate drug discovery, clinical research, trial execution, and medical writing.
“We are moving from the early phase of excitement around AI technologies in the life sciences space to figuring out how to apply these technologies to generate value and efficiencies,” said Chris Bouton. “I’m excited to identify applications of AI technologies that will help get life-saving medications to patients faster. This is a paradigm shift for the life sciences, and I am truly lucky to be working in this field.”
“Beyond his work developing the Certara.AI platform, Chris’s leadership style is an inspiration for all leaders at Certara,” said Robert Aspbury, President, Certara Scientific Software. “He takes an empathic, personalized approach, believing that people do their best work when they are doing something they love. As a leader, he identifies someone’s passions and strives to tailor the responsibilities of each team member to their interests.”
Since 2005, the PharmaVoice 100 has become one of the publication’s most anticipated features. From academia and nonprofits to Big Pharma, startups, and tech companies, it is the only awards program in the industry that honors individuals from all sectors of life sciences. These honorees, from the clinic to the C-suite, are making meaningful contributions to their fields and striving to improve outcomes for patients around the world.
Certara’s AI-powered solutions can be used to accelerate drug development timelines, enhance clinical trial design, and improve the quality of regulatory submissions. Click here for more information on Certara.AI.
About PharmaVoice
PharmaVoice is a leading industry publication operated by Industry Dive. Our stories deliver the most important voices and ideas in the life sciences to industry leaders.
Certara 소개
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.
Certara Contact:
Sheila Rocchio
sheila.rocchio@certara.com
Media Contact:
Alyssa Horowitz
certara@pancomm.com